Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O14862
UPID:
AIM2_HUMAN
Alternative names:
Absent in melanoma 2
Alternative UPACC:
O14862; A8K7M7; Q5T3V9; Q96FG9
Background:
Interferon-inducible protein AIM2, also known as Absent in melanoma 2, plays a pivotal role in innate immunity. It acts as a sensor within the AIM2 inflammasome, detecting double-stranded DNA in the cytosol and initiating pyroptosis, an inflammatory form of cell death. This process is crucial for the body's defense against pathogens and in response to cellular damage.
Therapeutic significance:
Understanding the role of Interferon-inducible protein AIM2 could open doors to potential therapeutic strategies. Its involvement in the regulation of inflammatory responses and cell proliferation suppression highlights its potential as a target in treating inflammatory diseases and cancer.